Impact of rTMS on Abnormal Cortical fMRI in Patients With Dystonia
Key facts
- Where
- Manhasset, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07626216, who can take part
Where in United States
- Northwell Health/Feinstein InstitutesManhasset, United StatesContact: Celina B Fernandez, MSTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Northwell Health
- Trial code
- NCT07626216
- Record updated
- 6 November 2026
- Original description
By tracking resting-state fMRI scans, we aim to discover how repetitive transcranial magnetic stimulation (rTMS) changes brain connectivity in individuals with dystonia.Read full original descriptionShow less
The Effect of Repetitive Trans-cranial Magnetic (rTMS) Stimulation on Abnormal Cortical Hubs Identified by Functional Magnetic Resonance in Subjects With Dystonia
By tracking resting-state fMRI scans, we aim to discover how repetitive transcranial magnetic stimulation (rTMS) changes brain connectivity in individuals with dystonia.
Inclusion: Male or female; 18 and 80 years of age; Patients who manifest dystonia - sustained involuntary movement of the head, neck, trunk or limbs; The dystonia may be spontaneous or genetic, specifically DYT1 or DYT6 and then only those patients who are demonstrating dystonia. The patient/subject will have a normal neurological exam except for dystonia.
Exclusion: No previous surgery for dystonia; Past history of head trauma, stroke, epilepsy, demyelinating disease; Hypertension in excess of 160mmHg systolic and 90mmHg diastolic; Congestive heart failure; Diabetes; Past psychiatric conditions: e.g., depression; Systemic metabolic disease: e.g., Wilson's disease, progressive neurodegenerative disease (like supranuclear palsy or corticobasal ganglionic degeneration); History or diagnosis of Parkinson's disease; Moderate to severe cognitive impairment (judged by a minimental status of <24.); Heredodegenerative dystonia of the type DYT8,9 or 10; Magnetizable incorporated metal parts - like pacemakers; Presence of myoclonus; Long term exposure to benzodiazepines, neuroleptics or anticonvulsants; No botulinum toxin within 12 weeks of baseline assessment and fMRI.